Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

Last updated: January 15, 2025
Sponsor: University Hospital, Bordeaux
Overall Status: Completed

Phase

N/A

Condition

Lupus

Vascular Diseases

Dermatomyositis (Connective Tissue Disease)

Treatment

blood sample

urine sample

Clinical Study ID

NCT03698071
CHUBX 2018/22
  • Ages > 18
  • All Genders

Study Summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of ANCA associated vasculitis according to the Chapel-Hill ConsensusConference - 2012 modified version

  • Age ≥ 18 years

  • being affiliated to health insurance

  • willing to participate and to sign informed consent.

Exclusion

Exclusion Criteria:

  • Pregnant or breastfeeding women,

  • patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of theirliberty by a judicial or administrative decision, minors, persons of legal age whoare the object of a legal protection measure or unable to express their consent)

Study Design

Total Participants: 32
Treatment Group(s): 2
Primary Treatment: blood sample
Phase:
Study Start date:
December 14, 2018
Estimated Completion Date:
May 23, 2022

Study Description

ANCA associated vasculitis are a rare group of diseases and potentially life-threatening inflammatory conditions. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Soluble CD95-L is a cleaved part of CD95-L which binds the CD95 Death receptor. s-CD95-L has pro-inflammatory properties for Th17 lymphocytes and Neutrophils, two cells implicated in ANCA associated vasculitis. It also plays a role in systemic lupus erythematosus (which present with the same type of renal glomerulonephritis as ANCA-associated vasculitis). Finally, it has already be found elevated in this group of diseases. The investigators hypothesized that s-CD95-L levels might be a prognostic factor in ANCA associated vasculitis and the study of the molecular mechanisms involved could provide new therapeutic targets.

The study will recruit 50 patients with ANCA associated vasculitis followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study s-CD95-L. Fundamental research will be realized on patients' sample to study molecular mechanisms involved.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same time as those drawn for clinical purposes.

Connect with a study center

  • CHU de Bordeaux - Service d'Immunologie et Immunogénétique

    Bordeaux,
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.